Decreased 1-25 Dihydroxyvitamin D3 Concentration in Peripheral Blood Serum of Patients with Thyroid Cancer

Low Vitamin D Status Is Not Associated With Thyroid Cancer Risk

“…Laney et al reported that serum 25(OH)D levels and the percent with 25(OH)D < 75 nmol/L were not different between 42 thyroid nodule, 45 thyroid cancer in remission, and 24 active thyroid cancer patients, and were not affected by cancer stage [12]. Stepien et al demonstrated that there were no significant differences when comparing serum 25(OH)D levels among individuals with multinodular goiter (34), thyroid cancer (27 papillary, 16 follicular, and seven anaplastic), and 26 healthy controls, although 1,25(OH) 2 D levels were significantly lower in thyroid cancer and advanced-stage disease [13]. Jonklaas et al found no association between preoperative 25(OH)D levels and a diagnosis of thyroid cancer, disease stage, or any other prognostic features [14].…”

“…For studies estimating vitamin D consumption and thyroid cancer risk, no convincing associations have been shown, maybe due to the general poor correlation between vitamin D deficiency and estimates of vitamin D consumption [7]. Several reports indicate no significant differences in vitamin D status between thyroid cancer patients and controls [11][12][13][14], while other groups reported the association of low serum 25(OH)D or 1,25(OH) 2 D levels and the incidence of thyroid cancer or poor clinicopathologic characteristics [13,[15][16][17]. Based on the anti-proliferative and pro-differentiating effects of vitamin D, the aim of this study was to examine serum 25(OH)D levels in patients with thyroid nodules and to investigate the correlation between low vitamin D status and the incidence of thyroid cancer and poor clinicopathologic characteristics.…”

The Anti-tumor Effects of Vitamin D in Other Cancers

“…There are few clinical studies of the vitamin D axis in thyroid cancer patients. Stepien et al reported lower circulating levels of 1,25(OH) 2 D among patients with papillary, follicular and anaplastic thyroid cancer [14]. We are aware of only a single clinical report of vitamin D administration in the treatment of thyroid cancer in patients.…”

Differentiation Therapy in Thyroid Carcinoma

“…VitD3 appears to be a good target for cancer therapy because decreased levels have been demonstrated in breast, prostate and colon cancer. The situation in TC is not clear: whereas one study reported normal VitD3 levels in TC patients, another study reported decreased VitD3 levels in TC, though not in goiter patients (Laney et al, 2010;Stepien et al, 2010). In cancers with proven deficiency VitD3 shows cytostatic effects and was tested successfully in a phase II clinical trial on prostate cancer (Srinivas & Feldman, 2009).…”